跳到正文
原文
MedPage Today·· 9 天前精选AI 评分70

VOLGA 试验确认 enfortumab vedotin 联合免疫检查点抑制剂作为肌肉浸润性膀胱癌的标准治疗

Enfortumab Vedotin-Based Treatment Solidified for Muscle-Invasive Bladder Cancer

AI 导读

VOLGA 试验显示 enfortumab vedotin 联合 durvalumab 治疗肌肉浸润性膀胱癌可改善无事件生存率和总生存率,但 adjuvant ev 的必要性仍有待确定。专家认为应根据患者情况决定是否需要 adjuvant ev 治疗。

推荐理由

讨论了 VOLGA 试验结果,强调了 ADC-IO 疗法在肌肉浸润性膀胱癌中的重要性。

正文

— Experts discuss survival gains and whether all patients need adjuvant therapy

by Gregory Laub, Senior Director, Video, MedPage Today

November 10, 2026 • 7 min read

In this exclusive roundtable video from MedPage Today, three expert leaders in the field of bladder cancer discuss the latest emerging data presented at the European Society for Medical Oncology (ESMO) congress.

Moderator Matthew Galsky, MD, of the Icahn School of Medicine at Mount Sinai in New York City, is joined by David Aggen, MD, PhD, of Memorial Sloan Kettering Cancer Center in New York City, and Stephanie Berg, DO, of the Dana-Farber Cancer Institute in Boston.

In this first of four episodes, they examine findings from the VOLGA trial, including the survival benefits of enfortumab vedotin (EV; Padcev) plus durvalumab (Imfinzi) and whether all patients need additional treatment following cystectomy.

Following is a transcript of their remarks:

Galsky: Hi everyone. Welcome to MedPage Today ESMO Roundtable on [genitourinary] cancers. And I'm Matt Galsky. I'm a medical oncologist focusing on bladder cancer at the Tisch Cancer Institute at Mount Sinai in New York. And I'm joined today by Dr. David Aggen from Memorial Sloan Kettering and Dr. Stephanie Berg from the Dana-Farber Cancer Institute. So welcome both of you. Thanks for joining.

Berg: Thank you.

Aggen: Thanks for having us, Matt.

Galsky: Absolutely. We had a pretty consequential set of data from ESMO this year on localized bladder cancer, both muscle-invasive disease and non-muscle-invasive disease. So over the next bit of time, I thought we would talk about some of the more important data, some of the potential practice-changing or practice-informing data, and would love to get your opinion on a set of studies that I think probably are the most important to talk about. And by the end of the discussions, I'm hoping that each of us can identify maybe immediate practice implication related to the data or an unanswered research question that you think should be tackled next.

So I thought we'd start with VOLGA, and I was going to present just a brief overview of the VOLGA study for the audience, and then would love to get your input on VOLGA. So just as a bit of context, we all know that from the KEYNOTE-905 and KEYNOTE-B15 studies in cisplatin-ineligible and cisplatin-eligible patients, respectively, that the regimen of perioperative enfortumab vedotin plus pembrolizumab [Keytruda] with cystectomy is a standard treatment approach for patients with muscle-invasive bladder cancer.

VOLGA tested a variation on this theme. So VOLGA enrolled patients who were cisplatin-ineligible or -declining and patients were randomized to receive either cystectomy alone, as was considered a standard of care at the time, or neoadjuvant treatment with enfortumab vedotin plus durvalumab for three cycles and then adjuvant durvalumab.

So a couple of differentiators from KEYNOTE-905: one, the use of durvalumab rather than pembrolizumab. The second is that in the adjuvant phase of treatment, there was no enfortumab vedotin given, which there was in KEYNOTE-905. In this study, it was only adjuvant immune checkpoint blockade. There was a third arm of the study and that included tremelimumab [Imjudo], a few doses of tremelimumab in the neoadjuvant and then one dose in the adjuvant setting, I believe.

The triplet regimen with tremelimumab demonstrated an improvement in disease-free survival, or event-free survival [EFS] rather, but not an improvement in overall survival [OS] -- yet. But the regimen of enfortumab vedotin plus durvalumab showed an improvement in event-free survival and an improvement in overall survival. The hazard ratios look pretty good, 0.51 for OS, 0.58. I'm sorry, 0.51 for EFS and 0.58 for overall survival. And I didn't really comment on the path CR [pathologic complete response] rates in the study, but would love to get your thoughts on that as well.

So Dr. Aggen, what do you think of this study? What does it add to the treatment of patients with muscle-invasive bladder cancer?

Aggen: I think that VOLGA really solidifies that enfortumab vedotin with a checkpoint is the standard for patients with muscle-invasive disease. The two phase III trials now in cisplatin-ineligible patients showing a huge benefit in terms of event-free and overall survival to giving neoadjuvant therapy.

I do think a couple key takeaways are that it's unclear the adjuvant contribution of enfortumab vedotin for some patients, and VOLGA really brings that into question, that some patients may not need enfortumab vedotin for an extended course after surgery. It's really on us to figure out who those patients are. There seems to be comparable EFS with a more limited duration of EV therapy.

The second thing though that's sort of of interest is the pathologic complete response rate in VOLGA, which was about 45% by investigator assessment and then closer to 40% actually when it was centrally reviewed. That is slightly lower than what we saw with all the caveats of cross-trial comparisons in EV-303/KEYNOTE-905 and EV304/KEYNOTE-B15.

And so I do think that's something that we're going to be talking about. A key theme of the meeting though in some of the other trials we may discuss later on is that path CR rate doesn't necessarily equate with long-term outcome. There were path CR rates with pembrolizumab in combination with cisplatin on the order of about 44% reported, and that did not equate to the same EFS and OS benefit.

So for me, the key takeaway is that for a patient with muscle-invasive disease, we should be having a conversation about ADC-IO [antibody-drug conjugate and immuno-oncology] therapy. I think that the onus is on us to figure out how much and who needs additional adjuvant treatment based on which regimen you select.

Galsky: Thank you. Dr. Berg, so Dr. Aggen mentioned that not everyone might need adjuvant EV, maybe not everyone needs adjuvant immune checkpoint blockade. Are there criteria that you use in clinic right now to determine what to do after surgery?

Berg: I think right now I'm still using the trial criteria and offering adjuvant, at least immunotherapy, and EV for those I think that can tolerate it. We all know radical cystectomy is quite tough and if you can try to get it in the window of time, but I completely agree with high-risk disease, it's important. But then if they have path CR or low risk, still T1 with a treatment effect, you really question is adjuvant anything needed, especially adjuvant EV.

And when you think about toxicities, like Dr. Aggen mentioned, especially with peripheral neuropathy, thankfully they were getting less EV in VOLGA, just the three cycles, but that can be really life-changing for patients and it's something that we really have to think about. What are we going to be doing for them if we eliminated micrometastasis and increasing that risk for permanent toxicity? So it's something I think the question isn't completely answered, but I think this data really helped at least bridge a little bit of the gap about having a broader discussion about adjuvant EV, and we're going to hopefully see some trials in this space.

And I just wanted to add that this also made me realize, and to tell our patients, that you can still get neoadjuvant treatment and go to surgery. I think it just confirmed that it's not really leading to more complications and it's really established how we're doing, as Dr. Aggen said, EV and ICI [immune checkpoint inhibitor], because I think we're not saying ICI specific now, and I'm sure once NCCN [National Comprehensive Cancer Network] gets a hold of it, we'll have a different wording for that language.

Galsky: Dr. Aggen, what do you make of the CTLA-4 blockade data? Sort of a checkered history in urothelial cancer so far.

Aggen: Unfortunately, it's been difficult to see a clear long-term benefit with CTLA-4 and bladder cancer like we've seen historically in kidney cancer. And it seems that the additional toxicity doesn't necessarily equate to an improvement in terms of pathologic complete response rates and not yet in terms of overall survival. Probably there's a subgroup of patients with immune-infiltrated tumors maybe that could benefit from CTLA-4, but I just don't think we have a clear sense of who those patients are at the moment.

Galsky: Thank you. So maybe one quick take home from both of you regarding VOLGA. How does this impact your practice Monday morning?

Berg: I can go first. I would say it fits in a sense that I'm going to say without cisplatin eligibility, I'm going to offer EV and ICI for patients prior to radical cystectomy if that's what they're choosing for their perioperative care. And that's what I'm going to go with.

Aggen: I think that if 10 years ago, Matt, we told Dean Bajorin that we'd have hazard ratios of 0.51 in muscle-invasive disease, he would've had a hard time believing us. I think that VOLGA reaffirms that ADC-IO therapy is the backbone of neoadjuvant therapy. And there's going to be, I think, a lot of shared decision making when it comes to adjuvant therapy. Certainly for patients with residual disease at cystectomy, those are patients who in my mind absolutely should continue ADC-IO therapy postoperatively.

Galsky: And I think you make a great point. We have two contemporary studies now with comparisons of systemic therapy with cystectomy versus cystectomy alone. It's pretty unusual to have that in solid tumors in this age where systemic therapy is integrated into clinically-localized disease across the board. So there's really no surgery-alone trials anymore.

So two contemporary studies both showing marked improvement in outcomes with perioperative systemic therapy. I think that really sort of seals the question about whether or not perioperative systemic therapy is needed in muscle-invasive bladder cancer. So thank you for those comments.

来源:MedPage Today · medpagetoday.com